Computational methods now give researchers practical ways to investigate the chemical complexity of Ayurvedic plants and formulas without experimentally testing every constituent at the outset. Molecular docking, network pharmacology, metabolomics, knowledge graphs, and machine-learning tools can rank compounds, targets, and pathways for later laboratory study. These methods do not “validate” a medicine or prove clinical efficacy; they generate testable hypotheses and reduce a very large search space to a smaller set of candidates.

The Problem Ayurveda Presents to Conventional Drug Discovery

Many early drug-discovery programs were organized around identifying one molecule that strongly modulates one selected protein. Modern pharmacology is broader and also uses phenotypic screening, systems biology, combination therapy, and polypharmacology. Nevertheless, complex herbal preparations remain difficult to study because they may contain many compounds whose concentrations vary with plant identity, plant part, cultivation, processing, extraction, and storage.

Triphala, for example, combines the fruits of Phyllanthus emblica, Terminalia chebula, and Terminalia bellirica. Its measurable chemical profile is therefore more complicated than that of a purified drug. Possible explanations for an observed biological effect include:

  • One constituent producing most of the measurable activity
  • Several constituents acting on the same or different targets
  • Additive, synergistic, or antagonistic interactions among constituents
  • Changes in solubility, absorption, metabolism, or distribution caused by the preparation
  • Indirect effects produced through interconnected cellular pathways

A classical co-administered vehicle or anupana should not automatically be described as a proven bioavailability enhancer. Whether a vehicle changes pharmacokinetics, tolerability, or efficacy must be established for the particular preparation through analytical and experimental studies.

The IMPPAT Database

The Indian Medicinal Plants, Phytochemistry And Therapeutics database, or IMPPAT, was first published in 2018 with 1,742 medicinal plants and 9,596 phytochemicals. IMPPAT 2.0 was released online in June 2022 and described in a 2023 ACS Omega paper. It expanded the resource to 4,010 Indian medicinal plants, 17,967 non-redundant phytochemicals, and 1,095 standardized therapeutic uses.

IMPPAT 2.0 also records plant-part–phytochemical associations, chemical structures, physicochemical properties, drug-likeness measures, and predicted ADMET information. Its authors compiled material from specialized books, pharmacopoeias, government publications, and research literature. These features make it useful for virtual screening, but a database entry confirms only that a compound has been reported for a plant; it does not establish how much of that compound is present in a particular medicine or whether it reaches a human target after oral administration.

How Network Pharmacology Analyzes Herbal Preparations

Network pharmacology links several kinds of information: plant constituents, predicted or experimentally reported protein targets, disease-associated genes, protein–protein interactions, and biological pathways. Researchers then use measures such as network degree and pathway enrichment to identify compounds or proteins that occupy central positions in the model.

A verified 2024 study examined Triphala in relation to obesity rather than cancer. After compiling 132 unique constituents, the researchers applied oral-bioavailability and drug-likeness filters and investigated predicted relationships with obesity-associated genes. AKT1 and PPARG emerged as prominent network targets, and several Triphala constituents were docked against them. The authors explicitly concluded that further experimental research was required. The analysis therefore proposed mechanisms; it did not demonstrate that Triphala prevents or treats obesity.

Material Studied Methods Main Computational Finding Evidence Boundary
Triphala Network pharmacology, pathway analysis, molecular docking AKT1 and PPARG prioritized in an obesity-related network Predictions requiring experimental and clinical confirmation
Bacopa monnieri Docking, molecular dynamics, binding-energy and ADMET calculations Bacopaside I prioritized as a possible BACE1-binding compound No demonstration of Alzheimer’s treatment in humans
AKBA from Boswellia X-ray crystallography and functional enzyme experiments Binding at an allosteric region of 5-lipoxygenase Target-level evidence, not proof of efficacy for every Boswellia product
Tinospora cordifolia LC–MS/MS metabolomics, network analysis, docking BACE1 and MAO-B proposed as neuroprotection-related targets Computational and metabolomic findings requiring validation
Butea monosperma stem bark LC–MS, network pharmacology, docking, molecular dynamics MAPK1, AKT1, MMP9, NF-κB, and RELA prioritized for ulcerative-colitis research The authors called for in-vitro and in-vivo confirmation

Verified Research Developments from 2025–2026

Recent work illustrates a shift from isolated docking exercises toward pipelines that combine authenticated plant material, chemical profiling, curated databases, target prediction, pathway analysis, and molecular simulation. This improves the biological context of a prediction, although it still does not replace laboratory or clinical evidence.

Bacopa Constituents and BACE1

A 2025 Scientific Reports study computationally compared selected Bacopa monnieri constituents with previously investigated BACE1 inhibitors. Bacopaside I produced the most favorable calculated binding free energy in that study, while bacopasaponin D and bacoside A3 were also prioritized. The work used docking, 150-nanosecond molecular-dynamics simulations, interaction analysis, and predicted ADME-toxicity profiles. These are lead-identification results only. Enzyme assays, pharmacokinetic studies, animal experiments, and controlled human trials would still be needed before claiming therapeutic BACE1 inhibition.

AKBA and the Structure of 5-Lipoxygenase

The frequently repeated claim that AKBA binding was first confirmed by crystallography in 2024 is incorrect. A structure published in Nature Chemical Biology in 2020 showed 3-acetyl-11-keto-β-boswellic acid bound between the membrane-binding and catalytic domains of 5-lipoxygenase, about 30 Å from the catalytic iron. Functional experiments indicated that AKBA altered the enzyme’s product pattern. This experimentally determined structure is stronger evidence than docking alone, but it does not establish that all Boswellia serrata extracts have equivalent composition, absorption, safety, or clinical action.

Withaferin A and Cancer Research

Withaferin A is a withanolide found in Withania somnifera and other Solanaceae plants. Computational and cellular work has investigated several proposed targets, including the Hsp90–Cdc37 chaperone complex. One published dose-escalation study evaluated a withaferin-A-containing formulation in 13 patients with advanced high-grade osteosarcoma and primarily assessed safety and pharmacokinetics. Separately, a recruiting Phase I/II trial is evaluating an ashwagandha intervention with liposomal doxorubicin in recurrent ovarian cancer. No efficacy conclusion should be drawn before results are reported.

Ayurvedic Knowledge Graphs in 2026

A January 2026 preprint combined Ayurvedic Pharmacopoeia information, IMPPAT phytochemicals, disease genes, approved-drug targets, pathway enrichment, a Neo4j knowledge graph, and molecular docking. The authors shortlisted 11 single herbal drugs and 188 phytochemicals for diabetes- and obesity-related analysis, highlighting targets including PTPN1, GLP1R, DPP4, and PPARG. Because this was a preprint and primarily computational, its proposed compound pairs and target relationships remain hypotheses rather than treatment recommendations.

Reverse Pharmacology: From Observed Use to Experimental Testing

Reverse pharmacology is widely discussed in Indian traditional-medicine research as a “clinic-to-laboratory” strategy. Instead of beginning with an untested chemical library, researchers begin with a documented traditional use or a carefully recorded clinical observation, standardize the material, evaluate safety and dose, and then investigate pharmacology and mechanism. The approach may help prioritize leads that already have some history of human exposure.

Traditional use, however, is not equivalent to demonstrated efficacy or guaranteed safety. Reliable reverse pharmacology still requires correct botanical identification, manufacturing controls, prospective clinical documentation, comparison groups where appropriate, adverse-event monitoring, pharmacokinetic analysis, and reproducible laboratory experiments.

Databases Supporting Current Research

Several genuine resources now organize Indian medicinal-plant information, but their contents and purposes differ. They should not be treated as interchangeable repositories of proven drug actions.

  • IMPPAT 2.0: 4,010 Indian medicinal plants, 17,967 phytochemicals, plant-part associations, therapeutic-use records, structures, and calculated properties.
  • GRAYU: a graph-based Ayurveda resource published in 2025 that integrates more than 12,000 plants, over 1,000 formulations, nearly 130,000 phytochemicals, and more than 13,000 disease terms.
  • CDMMM: a 2026 platform combining medicinal-plant information, DNA barcodes, metabolite fingerprints, and predicted target–disease associations. Its initial release included 67 plant species, 3,033 annotated metabolites, and 1,414 targets associated with 441 diseases.

Limitations and Critical Assessment

Docking predicts a plausible pose and produces a score from a simplified physical model. Results can change with protein structure, protonation state, ligand geometry, water molecules, receptor flexibility, and the scoring function used. A favorable score neither confirms physical binding nor reveals whether enough of the compound reaches the target in a living organism.

Network pharmacology has additional limitations. Predicted targets may be imported from algorithms rather than direct experiments; highly studied proteins can appear artificially central; enrichment analyses depend on the quality of the input gene list; and the presence of several compounds near one pathway does not by itself demonstrate synergy. Recent methodological reviews warn that herbal network-pharmacology papers require better chemical verification, transparent thresholds, suitable controls, and experimental validation.

Herbal materials also change during digestion and metabolism. Large glycosides may be poorly absorbed or transformed by intestinal enzymes and microorganisms, while metabolites absent from the original database may become the compounds that actually circulate. Plant species, plant part, extraction solvent, processing, dose, and batch quality must therefore be connected to the computational model.

Safety cannot be inferred from traditional use or a docking result. Herb–drug interactions, contamination, adulteration, excessive dosing, and individual susceptibility remain clinically important. Tinospora cordifolia, for example, has been associated with documented cases of clinically apparent liver injury despite extensive traditional use and promising laboratory research.

Computational research is consequently best understood as a prioritization system. It can identify compounds worth isolating, targets worth testing, analytical markers worth measuring, and combinations worth investigating. Confirmation still requires authenticated material, quantitative chemistry, target-binding or enzyme assays, cellular experiments, suitable animal models where justified, human pharmacokinetics, safety monitoring, and adequately designed clinical trials.

Practical and Safety Perspective

No patient should use a docking score, pathway diagram, preprint, or database prediction as evidence that an Ayurvedic product can treat cancer, Alzheimer’s disease, obesity, ulcerative colitis, or another diagnosed illness. Do not replace prescribed treatment or combine concentrated herbal products with medicines without consulting a qualified Ayurvedic practitioner and an appropriate healthcare provider, particularly during pregnancy, liver disease, cancer therapy, or treatment with medicines having a narrow therapeutic range.

References

  1. Nature (nature.com)
  2. Pubs (pubs.acs.org)
  3. Cb (cb.imsc.res.in)
  4. Mdpi (mdpi.com)
  5. Nature (nature.com)
  6. Rcsb (rcsb.org)
  7. Structural and mechanistic insights into 5-lipoxygenase inhibition by natural products (2020)
  8. Hsp90/Cdc37 chaperone/co-chaperone complex, a novel junction anticancer target elucidated by the mode of action of herbal drug Withaferin A (2011), PubMed
  9. Safety and pharmacokinetics of Withaferin-A in advanced stage high grade osteosarcoma: A phase I trial (2020), PubMed
  10. Clinicaltrials (clinicaltrials.gov)
  11. Nature (nature.com)
  12. Nature (nature.com)
  13. Arxiv (arxiv.org)
  14. Ayurvedic research and methodology: Present status and future strategies (2015), PubMed Central
  15. Frontiersin (frontiersin.org)
  16. Nature (nature.com)
  17. Molecular Docking: Shifting Paradigms in Drug Discovery (2019), PubMed Central
  18. Trends and Pitfalls in the Progress of Network Pharmacology Research on Natural Products (2025), PubMed Central
  19. NCBI

Nothing in this article diagnoses or treats a medical condition. Use it as educational information and consult a qualified Ayurvedic practitioner or physician before starting herbs, supplements, detoxes, or therapeutic protocols, especially if pregnant, managing a condition, or taking medication.

Tags: Ayurvedic Compounds Docking Drug Discovery In Silico Phytochemistry research